# A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

> **NCT01647828** · PHASE1,PHASE2 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 217 (actual)

## Conditions studied

- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** OMP-59R5
- **DRUG:** Gemcitabine
- **DRUG:** Placebo
- **DRUG:** Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT01647828
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01647828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01647828, "A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01647828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*